154 Results

People

  1. Stein
    Stein
  2. Nimer
    Nimer
  3. Tallman
    Tallman
  4. Goldberg
    Goldberg
  5. Levine
    Levine
  6. Papaemmanuil
    Papaemmanuil
  7. Rampal
    Rampal
  8. Bewersdorf
    Bewersdorf
  9. Horwitz
    Horwitz
  10. Klimek
    Klimek

Groups

  1. Department of Medicine (93)
  2. Hematologic Malignancies, Division of (82)
  3. Center for Hematologic Malignancies (81)
  4. Adult Leukemia (55)
  5. GSK Faculty (27)
  6. Hematology-Oncology Fellows (23)
  7. Executive Committee, Center for Hematologic Malignancies (18)
  8. Center for Molecular Imaging and Biotechnology (17)
  9. Tow Center for Developmental Oncology (TCDO) (17)
  10. Epidemiology and Biostatistics (16)
  1. "azacitidine"
Formats
  1. Journal Article (119)
  2. Review (20)
  3. Research Letter (7)
  4. Editorial (4)
  5. Meeting Abstract (3)
  6. Correspondence (1)
Groups
  1. Department of Medicine (93)
  2. Hematologic Malignancies, Division of (82)
  3. Center for Hematologic Malignancies (81)
  4. Adult Leukemia (55)
  5. GSK Faculty (27)
  6. Hematology-Oncology Fellows (23)

More Groups

People
  1. Eytan Stein (19)
  2. Martin Tallman (16)
  3. Jan Bewersdorf (10)
  4. Stephen Nimer (10)
  5. Aaron Goldberg (8)
  6. Elli Papaemmanuil (8)

More People

Years
  1. 2025 (7)
  2. 2024 (14)
  3. 2023 (17)
  4. 2022 (7)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Leukemia and Lymphoma (14)
  2. Blood Advances (10)
  3. Journal of Clinical Oncology (10)
  4. Blood (9)
  5. Blood Reviews (5)
  6. Journal of the National Comprehensive Cancer Network (5)

More Publications

Publishers
  1. American Society of Hematology (20)
  2. Taylor & Francis Group (19)
  3. Elsevier Inc. (13)
  4. American Society of Clinical Oncology (10)
  5. John Wiley & Sons (9)
  6. Nature Publishing Group (8)

More Publishers

Results (154)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
    Journal Article

    de Botton, S.; Cluzeau, T.; Vigil, C.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
    Journal Article

    Ruan, J.; Moskowitz, A.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Kotlov, N.; Nos, G.; Sorokina, M.; Maksimov, V.; Sboner, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • What’s next after hypomethylating agents failure in myeloid neoplasms? A rational approach
    Review

    Awada, H.; Gurnari, C.; Xie, Z.; Bewersdorf, J. P.; Zeidan, A. M.
    Cancers (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
    Journal Article

    Schnegg-Kaufmann, A. S.; Thoms, J. A. I.; Bhuyan, G. S.; Hampton, H. R.; Vaughan, L.; Rutherford, K.; Kakadia, P. M.; Lee, H. M.; Johansson, E. M. V.; Failes, T. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
    Journal Article

    Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M.; Stein, E. M.; Huntington, S. F.; Zeidan, A. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy
    Research Letter

    Zeidan, A. M.; Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E.; de Menezes, D. L.; Rose, S.; Boss, I.; Halene, S.; Haferlach, T.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • First results of a phase II study (STIMULUS-AML1) investigating sabatolimab plus azacitidine plus venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H. J.; Macias, G. R.; Sanford, D.; Luskin, M. R.; Stein, E. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Trial in progress: Phase Ib/II study of siremadlin in combination with venetoclax plus azacitidine in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)
    Meeting Abstract

    Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y. N.; Grzesiak, S.; Venditti, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save